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Prostate cancer (PCa) is the second leading cause of cancer death in men worldwide.
Most PCa deaths are due to osteoblastic bone metastases. What triggers PCa metas-
tasis to the bone and what causes osteoblastic lesions remain unanswered. A major
contributor to PCa metastasis is the host microenvironment. Here, we address how the
primary tumor microenvironment influences PCa metastasis via integrins, extracellular
proteases, and transient epithelia-mesenchymal transition (EMT) to promote PCa progres-
sion, invasion, and metastasis. We discuss how the bone-microenvironment influences
metastasis; where chemotactic cytokines favor bone homing, adhesion molecules pro-
mote colonization, and bone-derived signals induce osteoblastic lesions. Animal models
that fully recapitulate human PCa progression from primary tumor to bone metastasis are
needed to understand the PCa pathophysiology that leads to bone metastasis. Better delin-
eation of the specific processes involved in PCa bone metastasize is needed to prevent
or treat metastatic PCa. Therapeutic regimens that focus on the tumor microenvironment
could add to the PCa pharmacopeia.
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FOREWARD
Prostate cancer (PCa), one of the most common non-skin cancers,
results in the death of over a quarter million men annually world-
wide (1) and 2.7% American men are estimated to die from this
disease in their lifetime (2). The majority of PCa deaths are due to
the development of metastatic disease, 80% of which is primarily
localized in the bone (3). Furthermore, PCa induces an osteoblas-
tic reaction within the bone, which is rarely observed with other
bone-metastatic cancers.
For the patient who presents with metastatic disease, as evi-
denced by bone lesions detected by X-ray or it is suspected based
on a high Gleason score, the first line of treatment after surgical
removal of the primary tumor is androgen-deprivation therapy
(ADT). The majority of prostate tumors require androgen for
their growth and survival (4). Thus, the initial metastatic tumor
burden in a patient can be essentially eliminated and they appear
to enter remission. But the unfortunate fact is that some subpop-
ulation of these cells either harbor or develop resistance to ADT
and the tumor rapidly regrows.
Despite lack of evident dependence on circulating androgen,
these castration-resistant tumors are still highly addicted to andro-
gen and/or its cognate receptor, AR (5–8). Evidence for this is pro-
vided by several observations. First, second generation enhanced
anti-androgen therapies, such as Enzalutamide, are effective, even
if only for a while, in patients who failed the first round of ADT
(5). Second, recent evidence indicates the tumor itself turns on
androgen synthesis, so it no longer needs circulating androgen (9,
10). The successful use of drugs, such as Abiraterone (11), that tar-
get enzymes in the androgen synthetic pathway are also effective,
again albeit for a short time, in patients who failed ADT. Third,
the retention, mutation, and amplification of AR that accompanies
ADT-resistant tumors indicate a heavy dependence on AR for the
survival and continued persistence of these tumors. Several muta-
tions in AR are known to confer enhanced function and include
binding to other steroids or deletion of the ligand binding domain
resulting in constitutive activation (12, 13). Fourth,AR could inde-
pendently enhance invasion and metastasis through non-classical
steroid receptor signaling mechanisms (14, 15). Currently, there
are no approved therapies available that address these latter two
events.
Development of additional therapeutic regimes to target
metastatic tumors remains severely limited by the lack of knowl-
edge about (1) what triggers PCa metastasis in the first place, (2)
why it displays such a predilection for the bone, and (3) why it
induces an osteoblastic bone phenotype. The molecular events
thought to be involved in these three processes share a common
theme; i.e., interactions with the host, often referred to as the
tumor microenvironment. Current approved therapies are highly
focused on targeting events occurring intrinsically in the tumor
and do not fully consider the contributions of the host. Thus, bet-
ter understanding of the host and tumor interactions that trigger
and drive metastatic processes could provide additional avenues

























































Ganguly et al. Microenvironment of prostate cancer metastasis
for therapeutic intervention. In this review, we will discuss various
possible strategies by which PCa cell interactions with the sur-
rounding tumor microenvironment influence the development
of metastases, homing toward the bone, and the development of
osteoblastic lesions.
TUMOR MICROENVIRONMENT IN PROMOTING PROSTATE
CANCER METASTASIS
INTRODUCTION
It is widely accepted that the tumor microenvironment, or stromal
compartment, is biologically heterogeneous, consisting of various
cell types, such as fibroblasts, endothelial cells, and immune cells,
along with growth factors and cytokines, and numerous extra-
cellular matrix (ECM) components. Paracrine signals from these
factors released by the tumor activate signaling and gene expres-
sion in the neighboring cells and vice versa, ultimately setting up a
cycle of reinforcement and continued signal propagation. Interac-
tions between the cancer cells and this stromal compartment are
required for invasion, angiogenesis, and metastasis of cancer cells
to ectopic sites (16–18). The factors thought to drive the metastatic
progression of PCa and to play an important role in the interaction
of the tumor with its microenvironment are discussed below.
Olumi et al. (18), was the first to demonstrate the depen-
dency of PCa development on the underlying fibroblasts. It was
recognized that fibroblasts found near tumors, i.e., carcinoma-
associated fibroblasts (CAFs), were fundamentally different from
those in non-tumorigenic samples (19, 20). When CAFs isolated
from human PCa patients were mixed with initiated human non-
tumorigenic prostate epithelial cells, this was sufficient to initiate
tumorigenesis. Normal fibroblasts lacked this capacity, implicating
the importance of tumor-induced fibroblast effects feeding back
on the initiated tumor cells. In another study, prostate stromal
cells could replace Matrigel in LNCaP subcutaneous xenografts
to promote tumor growth. One effect of the stromal cells was
to promote angiogenesis (21). The stromal compartment of the
normal prostate gland is full of smooth muscle cells. However, in
PCa lesions, there was a dramatic loss of smooth muscle cells
that were replaced by cells displaying myofibroblast character-
istics, i.e., expression of Vimentin and increased production of
matrix remodeling enzymes like Collagen I and Tenascin (22).
This remodeling of the ECM and invasion of tumor cells into
the surrounding stromal compartment define a cancerous lesion,
as opposed to benign disease. The interaction of the prostate
tumor cells with the remodeled matrix and the contribution of
the tumor cells themselves to this process are critical first steps in
the movement of tumor cells out of their normal niche.
INTEGRINS IN PCa PROGRESSION
Integrins are a large family of cell-surface glycoproteins, which
form heterodimeric adhesion receptors. Integrins bind to a num-
ber of ECM components and regulate cytoskeletal organization
to maintain cell shape and facilitate migration. These interac-
tions also regulate cell survival, proliferation, adhesion, migration,
and invasion (23, 24). PCa initiation and progression is accom-
panied by preferential expression of integrin α6β1, reduction in
integrin α3β1, and complete loss of integrin β4 (25). Integrin α6,
a laminin receptor is associated with poor patient prognosis and
increased metastasis in a wide range of cancers (26, 27). In the nor-
mal prostate, integrin α6 complexed with integrin β4 is present at
the basal cell/stromal interface; however, loss of integrin polar-
ity occurs during progression of PIN to invasive cancer where
basal cells are lost and integrin α6 complexed with integrin β1
abnormally appears in the luminal-like compartment (28).
Integrin α6β1 was shown to play two major roles in PCa, pro-
moting cell survival and facilitating invasion and metastasis (28–
30). Within the normal prostate epithelium, integrin expression
is limited to the basal cells, being absent from the AR-expressing
luminal cells. However, during PCa development, integrin α6β1
becomes co-expressed with AR in the tumor cells (31). AR directly
binds the integrin α6 promoter and induces the expression of inte-
grin α6β1, while simultaneously decreasing integrin β4 expression
(29). Adhesion of PCa tumor cells to laminin to engage α6β1 pro-
moted AR-dependent survival of the cells. Survival was mediated
through AR-induced integrin α6β1 and subsequent activation of
NF-κB and Bcl-xL expression (29). This AR/α6β1 pathway was
active in metastatic cell lines, and elevated in castration-resistant
cells. Laminins are abundant in the bone microenvironment, with
Laminin-10 being the most highly expressed (32, 33), thus provid-
ing a mechanism for activating the integrin α6β1 survival pathway
in the bone. Elevated NF-κB activity plays a critical role in PCa
progression (34, 35). Another study demonstrated that secretory
proteins from prostate neuroendocrine cells activate NF-κB sig-
naling in the tumor cells, which in turn transcriptionally activates
AR in the tumor cells to promote castration-resistant cell growth
(36). The potential role of integrin α6β1 in this process remains to
be determined. It was previously shown that the integrin β1a vari-
ant is expressed in PCa tumors, while the β1c variant is present in
normal tissue (37). Signaling through the β1c variant was shown to
suppress p27kip, a major negative cell cycle regulator and tumor
suppressor known to be disregulated in PCa. Thus, a potential
α6β1a variant may contribute to PCa proliferation.
Integrin α6 remains the primary integrin expressed in lymph
node and soft tissue metastases, indicating high retention and
selection for this integrin during metastasis (38). Cleavage of
integrin α6 by uPA is associated with invasive PCa, the cleavage
product is detected in tumors but not in normal prostate tissue,
and promotes PCa cell invasion and migration on laminin (39, 40).
Furthermore, inhibiting integrin α6-mediated adhesion or cleav-
age delayed experimental lung metastasis (28, 41), reduced bone
growth in mouse femurs, and increased responses of metastatic
PCa cells to ionizing radiation (42, 43).
Laminin integrins like α6β1 and α3β1 associate with trans-
membrane scaffold and membrane organizing molecules called
tetraspanins (44). Tetraspanin KAI/CD82 was first identified as
a metastasis suppressor in PCa (45). Loss of CD82 in human
PCa correlates with poor prognosis, but by itself is not suffi-
cient to predict metastasis (46). Studies in PCa cell lines in vitro
demonstrate that CD82 is capable of suppressing integrin-based
functions including signaling, migration, and invasion (47–50).
CD82 regulates the internalization and turnover of integrins and
suppress integrin signaling through Met and Src (47, 48). Its role
in suppressing integrin functions was further validated in KO
mice. However, the dependency on integrins for its metastasis sup-
pressive functions did not prove to be valid (CKM, unpublished
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data). Furthermore, while restoration of CD82 to metastatic cells
suppresses metastasis, it loss in primary PCa is not sufficient to
induce metastasis in genetically engineered mice (CKM, unpub-
lished data). Thus, additional factors or as yet unidentified mecha-
nism is involved in CD82 suppression of metastasis. A more likely
target is its role in promoting cell–cell adhesion (51), discussed
further in the EMT section.
The importance of integrin α2β1 in PCa metastasis is also
emerging (31). Integrin α2β1 binds collagen, another major com-
ponent of the prostate basement membrane and bone microenvi-
ronment. Manipulation of integrin α2 expression in LNCaP cells
demonstrated a direct correlation between integrin α2 expression
and the ability to grow in the bone (52). RANKL expression in PCa
cells enhances bone metastasis. Integrinα2 integrin expression and
function was stimulated in PCa cells overexpressing RANKL (53).
Thus, many studies support the importance of integrins in PCa
development and progression by promoting, survival, prolifer-
ation, invasion, and metastasis. Targeting specific integrins and
their matrix interactions may provide a way to prevent metastatic
bone PCa.
PROTEASES IN PCa TUMOR INVASION AND METASTASIS
Breakdown of the basement membrane surrounding the prosta-
tic ducts and invasion of prostate cells into the stromal com-
partment defines the pathology of prostate adenocarcinoma.
Proteases that mediate basement membrane and stromal ECM
degradation are crucial for this process and represent the first
steps toward metastatic dissemination (Figure 1). Penetration
into and out of the vasculature and lymphatics similarly requires
proteases (54, 55).
Type II transmembrane serine proteases, like Matriptase and
Hepsin, which are important for normal epithelial tissue devel-
opment and repair, contribute to the breakdown of the basement
membrane in PCa (56). Hepsin is dramatically up-regulated in
PCa and represents one of the most highly overexpressed proteins
in PCa microarrays (57). Elevated Hepsin expression is associ-
ated with high Gleason score and poor clinical outcome (55, 58,
59). Hepsin overexpression in the prostate epithelium causes dis-
organization of the basement membrane and its overexpression
in PCa cell lines promotes lymph node metastasis (57). Hepsin
reportedly cleaves and activates pro-HGF produced by activated
fibroblasts within the stroma, thereby activating the receptor tyro-
sine kinase Met signaling pathway; a known activator of epithelial
cell scattering, migration, and invasion (60). However, it was also
reported that another Hepsin target is Laminin-5, a major com-
ponent of the prostatic basement membrane, which is lost during
PCa development (61).
Matriptase is expressed in many cancers and increased expres-
sion is seen in primary prostate tumors and metastatic lesions
(62–64). One of its reported targets is Laminin-5, deposited in the
prostatic duct basement membrane primarily by the basal epithe-
lial cells. Laminin-5 expression is lost in PCa, coinciding with the
FIGURE 1 | Interactions of PCa cells with an extracellular matrix
that is remodeled by cancer-associated fibroblasts, and soluble
factors and proteases released within the tumor microenvironment
induce EMT and subsequent invasion and dissemination of cancer
cells. In the primary tumor microenvironment, the epithelial cancer cells
are surrounded by the cancer-associated fibroblasts (CAF), pericytes,
and various extracellular matrix (ECM) proteins. This tumor
microenvironment produces various factors like TNFα, TGFβ, Wnt, and
HIF-1α which promote EMT via up-regulation of specific transcription
factors. EMT programing leads to a mesenchymal phenotype of the
cancer cells and with the help of various proteases (MMPs, Matriptase,
Hepsin), the cancer cells cleave the ECM, break away from the tumor
microenvironment and intravasate into the blood vesicles to travel to
distal organs.
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loss of its primary receptor, integrin β4 (65). Active degradation
combined with loss of secretion within the emerging PCa cells
likely accounts for the lack of Laminin-5 in PCa tumors. Whether
Laminin-10, another component of the prostate basement mem-
brane, which is not lost during PCa development, is also cleaved
by Matriptase or Hepsin is not known.
While Hepsin expression is apparently not controlled by AR,
both Matriptase expression and its cleavage is highly controlled by
androgen signaling (66). Rapid cleavage within minutes of andro-
gen stimulation, mediated by Src signaling, is followed by a more
long term increase in new Matriptase mRNA, thus providing a
mechanism for replenishing depleted pools. Because Matriptase
is essential for detachment of epithelial suprabasal cells during
skin differentiation (67), and the AR-positive luminal cells also
must detach upon differentiation, it is highly likely that Matrip-
tase is also important in prostate epithelial differentiation. That
AR, within the newly emerging luminal cells, can control integrin
expression and a protease that degrades basement membrane has
interesting implications about how AR contributes to preserving
a luminal phenotype and may promote loss of basal cells during
PCa development (68).
Two other proteases, which are known direct AR transcrip-
tional targets, PSA and TMPRSS2, are normally secreted into the
lumens of prostatic ducts (69, 70). However, due to loss of epithe-
lial polarization and invasion into stromal areas, these enzymes
are now also present within the tumor microenvironment (71).
Their relative importance in PCa development or progression has
remained largely undetermined.
The most extensively studied proteases linked with invasion
and metastasis are the matrix-metalloproteinases (MMP). MMPs
are involved in the degradation of the stromal ECM components
such as Collagen and Fibronectin (72, 73). In normal tissues,
MMPs play a major role in ECM remodeling involved in develop-
ment and tissue repair. Their misregulation contributes to many
disease states, including rheumatoid arthritis, pulmonary emphy-
sema, and tumor invasion and metastasis (74–77). Active MMPs
are secreted mainly from the cells in the tumor microenvironment,
such as connective tissue, fibroblasts, endothelial cells, osteoblasts,
macrophages, and neutrophils but also by cancer cells. Active
MMPs are used by cancer cells to invade the stromal compartment
both at the primary site and at metastatic sites (75, 76).
In PCa, MMP-2 and -9 are considered useful prognostic mark-
ers and these MMPs promote invasion and metastasis of PCa
cells (78, 79). Elevated levels of MMP-2/9 in serum or plasma
are correlated with high Gleason score (78–80). Overexpression of
MMP-1 promoted PCa cell invasion and experimental metastasis,
and inhibition of MMP-1 activity decreased PCa tumor growth in
mice, indicating the importance of MMP-1 in regulating PCa inva-
sion and metastasis (81). Induction of PCa invasion by MMP-9 is
mediated through cleavage and subsequent inactivation of the ser-
pin protease nexin-1 (PN-1). PN-1 is known to inhibit urokinase
plasminogen activator (uPA) and thus inhibits PCa progression
and metastasis (82). uPA and its receptor (uPAR) promote PCa
metastasis, as down regulation of uPA or uPAR inhibited PCa
cell invasion and metastasis (83, 84). When this is coupled with
the reported role of uPA in cleaving integrin α6 (39), it becomes
apparent how concerted efforts of proteases and integrin-based
cell adhesion work together to promote invasion and metastasis.
Attempts to therapeutically target the MMPs, as a whole class,
failed in clinical trials; resulting in worse outcomes (85). The lack
of specificity to specific MMPs and the unforeseen protective role
of some MMPs are thought to have contributed to the failure.
Thus, there has been much resistance to trying to identify specific
MMP inhibitors. On the other hand, preclinical testing of a small
molecule Hepsin inhibitor demonstrated it blocked PCa metas-
tasis in a genetic mouse model (57). Curcumin has the capacity
to inhibit androgen induced Matriptase activation and displays
anti-metastatic properties (86). Antibodies that block Matriptase
cleavage have been reported (87), and a natural protein product
produced by bacteria, Ecotin, is a natural Matriptase inhibitor
(88), either of which may offer a therapeutic advantage. More
work in defining the protease targets and mechanisms for inducing
invasion and metastasis is clearly warranted.
EPITHELIAL-MESENCHYMAL TRANSITION IN PROMOTING PCa
METASTASIS
The steps that lead to PCa metastasis (Figure 1) include degrada-
tion of the ECM, detachment of the cancer cells from the ECM as
well as their detachment from each other, migration toward and
subsequent entry into the blood or lymphatic system (89–91). The
machinery and signaling pathways used in these invasive events are
part of the normal wound healing response of epithelial tissues.
Upon tissue damage, a host of growth factors and cytokines are
released from the blood stream that activate the stromal fibroblasts
(PDGF, TGF-β), endothelial cells (VEGF, FGF, IL8), and epithelial
cells (HGF, TGF-β) to repair the tissue and fill in the wound (92).
Through these signals epithelial cells are forced to loosen their
matrix adhesions via activation of proteases and integrin signal-
ing, and are induced to migrate across matrix being remodeled by
the stroma. Some may even detach from each other to facilitate
filling in the wound. It is this latter event, loss of cell–cell adhesion
and depolarization of epithelial cells that is thought to trigger the
final conversion of primary cancer cells into metastatic ones. Once
loosened from the matrix and from each other, these cells are now
free to roam if they have acquired the proper mutations that allow
them to survive as non-adherent cells.
This process is referred to as epithelial–mesenchymal transition
(EMT), where the loosened epithelial cells take on the physical
properties of mesenchymal fibroblast-like cells (92). The clas-
sical marker of EMT is cadherin switching; where E-Cadherin
expression is lost and N-Cadherin is gained (89, 90). E-cadherin,
which promotes homotypic binding between two adjacent epithe-
lial cells, prevents the cancer cells from breaking away from each
other and reinforces tight junctions to preserve epithelial barrier
function and apical/basal polarity (90, 93). The metastasis sup-
pressor, tetraspanin CD82, promotes E-cadherin-based cell–cell
adhesion, and suppresses integrin-based migration (51). Loss of
this crucial regulator reduces cell–cell adhesion, while at the same
time promoting enhanced migration; thus, its loss would strongly
facilitate an EMT-like phenotype. Decreased CD82, E-Cadherin,
or β-catenin (the anchoring protein for E-cadherin) is associated
with poor PCa prognosis (23, 46, 94, 95). TGF-β is the most classi-
cal inducer of EMT, signaling through Smad family transcription
factors to induce the expression of the EMT-regulating tran-
scription factors Snail, Slug, Zeb-1, and/or Twist (96–100). These
EMT-associated transcription factors, through interactions with
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epigenetic regulators, control expression of genes involved in cell
polarity, cell–cell contact, cytoskeleton structure, and ECM degra-
dation (Figure 1), including repression of the E-cadherin gene
(101).
While EMT is well-established in several other epithelial cancer
types, its specific role in PCa remains controversial. This is com-
plicated by the histological data demonstrating that PCa remains
very epithelial-like in both primary tumors and in metastatic tis-
sues; expressing E-cadherin and other classical prostate epithelial
markers (94, 102). Yet, a few isolated tumor cell lines, especially
those that have lost AR expression, readily adapt EMT pheno-
types and are relatively invasive and metastatic (102–104). The
necessary presence of AR in PCa tumors, which drives a luminal
differentiation phenotype may make the conversion to EMT a rel-
atively difficult process (103). It might explain the long latency for
conversion of primary PCa to metastatic disease (105). The het-
erogeneous display of EMT phenotypes in PCa and other human
tumor samples, has fueled the hypothesis that EMT is a transient
process necessary for escape and dissemination, that reverses back,
i.e., MET (mesenchymal epithelial transition) when cells reach
their distant sites. A study that tested this hypothesis using a Tet-
inducible model, demonstrated that transient induction of EMT
was required for the migration of squamous carcinoma cells out
of the skin into the blood stream, and subsequent shut off was
required to establish metastatic tumors in the lung (106). If this
happens in PCa is not clear, and the factors that drive it are even
less clear.
The soluble factors that are secreted into a wound by physical
disruption are the same factors present in the tumor microen-
vironment. Transforming growth factor-β (TGF-β) is a potent
inducer of EMT and is released by many cellular components of the
tumor microenvironment. However, the ability of primary tumors
to respond to TGF-β is hindered by the normal growth inhibitory
effects of TGF-β signaling, and thus the tumor cells typically block
this pathway. So the cells must find ways to reactive some aspect
of TGF-β signaling that doesn’t cause growth suppression or find
other indirect ways to stimulate EMT. One study suggested that
direct cell–cell contact between tumor cells and platelets synergis-
tically cooperated with TGF-β, to directly activate NF-κB signaling
in the tumor cell to promote EMT and metastasis (107).
Inflammation induced during wound healing and in tumors
also impacts the behavior of tumor cells. Many studies have
demonstrated that wounding is a tumor-promoting event, espe-
cially chronic wounding where inflammation is high (92). The
role of inflammation in PCa initiation was originally identified
histologically by the presence of prostate inflammatory atrophy
(PIA) in tumor samples (108). Recent mouse studies demon-
strate that prostatic inflammation induced by prostitis, enhances
basal-to-luminal differentiation and accelerates the initiation of
PCa (109). Two sources for inflammatory signaling in PCa have
been proposed, the stromal cancer-associated fibroblasts (110)
or mesenchymal stem cells (111). A recent study highlighted the
importance of adipocytes in inducing inflammatory responses in
PCa cells within the bone through the lipid chaperone FABP4,
triggering IL-1β expressing and oxidative stress protein HMOX-
1 (112). Other studies proposed the inflammatory responses in
PCa are mediated through NF-κB signaling (113). Inflammatory
cytokines like TNFα and interleukins produced by both tumor
cells and surrounding cells (114) activate NF-κB signaling and
one consequence of this is the release of TGF-β (115, 116).
Non-TGF-β pathways can also activate EMT. TNFα can act
independently of TGF-β to induce EMT by repressing GSK-
3β, activating the AKT pathway, and stabilizing Snail (117–119).
Wnt signaling also stimulates EMT in PCa cells. Expression of
SOX2 induces EMT, and this was shown to be mediated by
SOX2 binding to and activating β-catenin (120). The PCa-specific
fusion and oncogene, TMPRSS2-Erg, enhances cell invasion (121,
122). Manipulation of the fusion gene in VCaP cells, altered
Frizzled4 (Fzd4) expression (123). Fzd4 signaling promoted cell
adhesion-related EMT phenotypes in VCaP cells. HIF1α, acti-
vated under hypoxic conditions, promotes aggressive tumor cell
invasion and metastasis (124, 125). Overexpression of HIF1α in
some PCa tumor cell lines promoted EMT that was dependent on
β-catenin (126).
Further demonstration that EMT/MET phenotypic conver-
sions are essential for the progression and metastasis of PCa to the
bone is highly warranted. While current mouse models have been
effective at defining specific molecular events occurring within
the primary tumor or bone-resident tumors, the process whereby
a confined prostate tumor is converted to a metastatic bone tumor
has not been adequately modeled. The models do not currently
reflect what is observed in human patients; i.e.,AR-positive epithe-
lial cells that migrate to and take up residence in the bone to
induce an osteoblastic bone reaction. Understanding the specific
genetic and epigenetic alterations that promote EMT-like phe-
notypes in PCa will be important to understanding the switch
between indolent and lethal PCa, improving staging and prognosis
of PCa patients and preventing over treatment.
TUMOR MICROENVIRONMENT IN PROSTATE CANCER BONE
HOMING AND COLONIZATION
SECRETED FACTORS IN PCa BONE HOMING
Different types of cancers develop metastases in very specific
organs. Several secreted factors have been proposed to promote
organ-specific homing (Figure 2). A few of these chemotactic
signals can attract cancer cells toward the bone. Conditioned
media from osteoblasts differentiated in vitro served to induce
migration and invasion of breast and melanoma cells, indicating
osteoblasts secrete potent factors that can induce metastasis to the
bone (127, 128). Osteonectin, a purified active factor from the
bone, promoted invasion of bone-metastatic cancer cells, but not
the non-bone-metastatic cancer cells indicating that bone possess
chemotactic factors that can promote tissue-specific homing of
cancer cells (129). It was demonstrated that osteoblast conditioned
media containing higher amounts of TGF-β promoted chemotaxis
and invasion of PC3 cells. Given the abundance of TGF-β in the
bone environment, it could act as a chemo-attractant of PCa cells
to the bone (130).
Chemokines and cytokines have chemo-attractant properties
that play an important role in the cancer cell proliferation, sur-
vival, and gene transcription. Chemokine receptors are involved
in many processes of cancer metastasis (131, 132). Mice bear-
ing autoimmune arthritis have higher incidence of breast cancer
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FIGURE 2 | PCa cells home to bone by chemo-attractants and
colonize through direct association with osteoblasts, where the PCa
cells secrete factors that promote osteoblastic responses and the
osteoblasts reinforce tumor cell survival and growth. Expression of
various chemo-attractants (Osteonectin, TGFβ, CXCL12, VEGF) guide PCa
cells to extravasate and home toward the bone. Once in the
bone-microenvironment the cancer cells interact with bone-forming
osteoblasts via Cadherin-11. Factors like BMP, ET-1, Wnt, or PDGF,
secreted from the cancer cells promote the proliferation and
differentiation of osteoblasts. In turn the bone-microenvironment
secretes soluble factors like FGF, IGF, and TGFβ to promote tumor cell
survival and proliferation.
metastasis to the bone, which was proposed to be due to the pres-
ence of higher amounts of circulating levels of pro-inflammatory
cytokines in these autoimmune arthritic mice (133).
The chemokine receptor, CXCR4, and its ligand CXCL12/SDF
are widely studied in PCa bone metastasis (134, 135). In bone mar-
row, CXCL12 is expressed in osteoblasts, fibroblasts, and endothe-
lial cells (136). Blocking CXCR4 in PCa cells using neutralizing
antibody inhibited the dissemination and colonization of PCa cells
in mice tibia following intra-cardiac injection (135). Akt1 report-
edly induces the expression of CXCR4 in PTEN-null PCa cells, and
overexpression of Akt-1 promoted intra-tibial tumor growth of
PCa cells (137). These results indicate that Akt-1 might be induc-
ing the CXCR4/CXCL12 axis and thus promoting PCa metastasis.
PCa cells home toward areas in the bone marrow rich in osteoblasts
where the hematopoietic stem cell (HSC) niche resides. In fact,
PCa cells can bind to and displace mouse HSCs from the niche.
Furthermore, the cancer cells egress out of the HSC niche into
the blood when CXCR4 signaling is blocked by AMD3100 (138).
These findings suggested that the CXCL12/CXCR4 axis is impor-
tant for chemotaxis of PCa cells to the bone. However, inhibiting
CXCR4 with CTCE-9908, a drug approved by FDA for osteosar-
coma, inhibited spleen, liver, and lymph node metastasis of PCa
cells, indicating CXCR4 may be a common metastatic factor, rather
than one that is bone specific.
ECTOPIC SITE PRE-REMODELING
The famous “Seed and Soil” hypothesis, put forward more than
100 years ago by Dr. Stephen Paget, was used to explain why differ-
ent types of cancer preferentially metastasize to different specific
tissues. The theory proposed that distant organs, like the bone,pro-
vide a preferred “fertile soil” for cancer cells, and the cancer cells
were preferentially attracted to that tissue. However, Isaiah Fidler’s
group demonstrated that tumor cells were present in vasculature
of all the organs, yet metastasis only developed in certain organs
but not in others (139, 140). David Lyden’s group put forward the
pre-metastatic niche model, where remodeling of only the pre-
ferred ectopic site(s) for metastasis occurs much earlier, before the
cancer cells even break away from the primary tumor (139).
The niche remodeling events, mediated by soluble factors acting
on non-cancer cells, govern the route of dissemination of can-
cer cells to a specific microenvironment. They demonstrated that
bone marrow-derived hematopoietic progenitor cells expressing
VEGF receptor 1 (VEGFR-1), homed to the specific metastatic
sites through integrin α4β1. At the same time, the tumor cells
secrete factors that induce the fibroblasts within the pre-metastatic
niche to secrete Fibronectin, an α4β1 ECM ligand. The VEGFR1-
positive cells then promote chemo-attraction and adherence of
circulating tumor cells (141). Consistent with this idea, Hirut-
suka et al. (142) demonstrated in a mouse model of melanoma
metastasis that VEGF-A, TGF-β, and TNF-α released from the pri-
mary tumors induced the expression of chemokines in the lung
parenchyma but not in other organs. In another study, persis-
tent STAT3 activation was detected in distant organs such as the
lung before tumor cell arrival. S1PR1–STAT3 up-regulation in
tumor cells induced S1PR1–STAT3 at these distant sites and in
myeloid cells. Ablation of STAT3 in the myeloid compartment
inhibited STAT3 activity in the lungs, inhibited formation of pre-
metastatic niche, and inhibited lung metastasis (143). Whether a
similar pre-metastatic niche remodeling and non-tumor cell sig-
naling governs PCa bone metastasis is not known. However, a
past study demonstrated enhanced bone metastasis of orthotopic
xenografted human cell lines upon androgen ablation (144). ADT
in human PCa patients induces bone loss that is often corrected by
bisphosphonates (145). Similarly, castrated mice lose bone mass
(146). The full contribution of ADT to pre-metastatic niche con-
ditioning, bone metastasis, osteoblastic reactions, or emergence of
castration-resistant disease, as a result of bone-microenvironment
interactions needs further investigation.
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ADHESION MOLECULES IN PCa COLONIZATION
Several studies have suggested that the choice of metastatic organ
is not necessarily dictated at the time tumor cells escape the tumor
and end up in the circulation. Circulating tumor cells can be
found in patients who do not have or do not develop metasta-
tic disease (147). Furthermore, tumor cell entry is not restricted
to specific organs, majority of circulating tumor cells extrude
into tissues (147, 148). A PCa study demonstrated that 50% of
the patients with primary tumors had circulating tumor cells as
well as tumor cells lodged in the bone (149), yet only 12–13%
of these patients ever develop metastatic disease. Thus, additional
events are required for the tumor cells to grow and colonize the
metastatic site.
Cadherin-11, commonly known as osteoblast cadherin, is pri-
marily found in osteoblasts, with very low but detectable expres-
sion in brain, testis, and lung (150, 151). It is an adhesion molecule
that mediates many steps of osteoblast maturation (150, 151).
Cadherin-11 expression is increased in metastatic PCa compared
to primary tumors but is not present in normal prostate tissue.
Furthermore, elevated Cadherin-11 was found in human PCa
bone metastasis relative to lymph node metastasis (152), indi-
cating cadherin-11 is specifically associated with bone metastasis.
Cadherin-11 may mediate the binding of cancer cells to osteoblasts
(Figure 2). Such binding might also promote cross talk between
cancer cells and osteoblasts and induce osteoblastic lesions. Intra-
cardiac injection of PC3 cells expressing Cadherin-11-specific
shRNA displayed a significant decrease in bone metastasis com-
pared to the control cells (152). PCa cells derived from bone
express high levels of cadherin-11, and expression of cadherin-
11 in PCa cells promoted PCa cell invasion and migration and
increased the adhesion and intercalation between osteoblasts in
an in vitro culture model (153). Another group demonstrated
that bone-tropic MDA-MB-231 breast cancer cells also express
high levels of cadherin-11 compared to brain-tropic MDA-MB-
231 cells. Thus, cadherin-11 is likely an important determinant of
bone-tropism in cancer cells (154).
TUMOR MICROENVIRONMENT IN PROMOTING
OSTEOBLASTIC LESIONS
Breast cancer metastasis is usually osteolytic (bone degrading);
however, PCa is osteoblastic, i.e., leading to new bone formation
(155, 156). It has been reported that some colon and cervical can-
cers are also osteoblastic (157). The exact mechanisms by which
osteoblastic versus osteolytic metastases occur is still unclear.
However, the differences are likely to reside in the differential inter-
action of tumor cells with the bone microenvironment. Bone,
a dynamic connective tissue is constantly remodeling during an
individual’s lifetime. The process of remodeling is dependent on
two cells types, osteoblasts and osteoclasts, both of which work in
harmony to maintain the normal bone. Osteoblasts derived from
mesenchymal stem cells in the bone marrow, make new bone.
Whereas osteoclasts, which are modified macropages derived from
monocytes, degrade bone (84). During osteoblastic metastasis, the
bone remodeling favors bone formation over resorption.
FACTORS THAT INDUCE OSTEOBLASTIC BONE METASTASIS
The number of osteoblasts surrounding PCa cells is increased in
osteoblastic bone metastasis (155). However, the newly formed
bone is weak and fragile, lacking mechanical strength. These
bones are composed of randomly orientated and loosely packed
collagen bundles, resulting in weak bone strength and fre-
quent fracture (158). Furthermore, the excessive bone growth
disrupts the bone marrow compartment, reducing immune
function. Many factors can induce the growth and differen-
tiation of osteoblasts and their precursors (Figure 2). Tumor
cells secrete many of these factors, and thus may actively pro-
mote osteoblastogenesis.
Bone morphogenetic proteins
Bone morphogenetic proteins are members of the TGF-β super-
family and various isoforms of BMP promote both prostate and
breast cancer metastasis (159, 160). One major source of BMP
expression appears to be from the tumor cells. Elevated expres-
sion of both mRNA and BMP-6 protein is detected in primary
PCa tissues and in PCa cell lines (161, 162). BMPs could influ-
ence metastasis by acting directly on the tumor cells or through
their effects on the bone microenvironment. For instance, BMP-2
induces resistance to apoptosis due to hypoxia (163) and promotes
breast cancer cell invasion and migration (164); whereas, BMP-6
promotes migration and invasion of PCa cells (161). BMP-2 and -7
stimulated cellular migration and invasion of PCa cells (165), and
BMP-6 acting through Smad signaling directly induced the tran-
scription of extracellular proteases such as MMP-1 and 9, required
for invasion (159).
Findings from genetically modified mice demonstrate that the
normal role of BMPs in the bone is to induce the differentia-
tion of osteoblasts (166, 167). For example, BMP-7 knockout mice
have smaller skeletons and reduced mineralized bone (168). The
ability of BMP-7 to control bone mineralization or osteoblast dif-
ferentiation can be attributed to the induced expression of crucial
differentiation factors, Runx2 and Osterix, in bone stromal cell
precursors (169, 170). High BMP-7 expression was detected in
PCa-induced bone lesions, while its expression in primary tumors
is low (155, 171). However, its exact role in promoting osteoblastic
vs. osteolytic lesions remains controversial. Nonetheless, BMP-7
produced by tumor cells has the potential to impact osteoblast dif-
ferentiation within PCa bone lesions. The most intriguing aspect
of BMP-7 is that while its expression is controlled by androgen and
it is required for normal prostate development, the most elevated
BMP-7 expression was observed in castration-resistant tumors
within the bone (171). However, BMP-7 expression in prostate
bone tumors appears to be largely growth suppressive and may
promote PCa cell dormancy (172).
Elevated BMP-6 expression is also associated with PCa bone
metastasis (159). BMP-6 produced by cancer cells was able to
induce mineralization of M3T3 pre-osteoblasts, and blocking
BMP-6 activity reduced osteolastic lesion formation by LuCaP 23.1
cells in vivo (161). Two studies demonstrated that Wnt5a or Wnt3a,
generated by bone stroma cells, induces the expression of BMP-6 in
PCa cells (173, 174). This was mediated by non-canonical JNK and
canonical β-catenin signaling pathways, respectively (174). The
induction of BMP-6 by Wnt5A secretion occurred in the absence
of androgen and promoted androgen-independent growth of
the tumor cells (173). Interestingly, in a recent patient-derived
bone xenograft model, transplantation of human bone-metastatic
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tumors into the bone, but not in the skin, resulted in castration-
resistant tumor growth (175). Thus, the bone microenvironment
has a high capacity to influence PCa treatment. The BMPs secreted
by PCa cells through Wnt signaling, in turn induce the differ-
entiation of osteoblasts. For instance, BMP-4 produced by PCa
cells promoted osteoblast differentiation of mouse stromal cells,
as measured by the production of alkaline phosphatase, osteocal-
cin, and collagen type II. At the same time, BMP-4 also stimulated
the production of sonic hedgehog (Shh) by the tumor cells (176).
Shh stimulated Smad1 and BMP receptor expression in the mouse
stromal cells, which enhanced their response to BMP-4. The ability
of Shh to induce osteoblast differentiation was promoted by colla-
gen production and was Gil1-dependent, but Runx2-independent
(177, 178). Thus, BMPs and Shh cooperatively provided cues for
the growth of PCa cells and the differentiation of bone stromal
cells. All these results indicate that BMPs and Shh from the PCa
cells play an important role in inducing osteoblast differentiation
from bone stromal cells, and thus likely contribute to osteoblastic
bone phenotypes.
Endothelin 1
Endothelin 1, a potent vasoconstrictor along with other family
members ET-2 and ET-3, is produced by the vascular endothe-
lium. Plasma levels of ET-1 are elevated in several types of cancers,
including PCa (179). ET-1 inhibits PCa cell apoptosis via enhanced
Bcl-2 family member expression and PI3K/Akt activation (180). In
ovarian carcinoma cell lines, ET-1 promotes invasion via the acti-
vation of extracellular proteases like MMP-1 (181). In addition
to promoting cancer metastasis, ET-1 promotes osteogenic prop-
erties; ET-1 null mice exhibit hypoplasia of facial bones (182).
ET-1 is a potent mitogenic factor of osteoblasts and patients with
osteoblastic bone lesions have increased serum levels of ET-1 (171,
183). Elevated ET-1 might contribute to osteoblast proliferation
and differentiation (184–186).
In clinical trials, atrasentan (endothelin A receptor antagonist)
suppressed bone remodeling in castration-resistant metastatic
patients (187). However, atrasentan in combination with doc-
etaxel, a chemotherapeutic agent, did not improve progression-
free survival in castration-resistant bone-metastatic patients (188).
One of the potent pathways by which ET-1 promotes osteoblast
activity is through the activation of Wnt signaling via the
inhibition of the Wnt suppressor DKK1 (189). ET-1 inhib-
ited DKK-1 expression, but also increased the expression of
Type 1 collagen, a predominant protein constituent of bone
matrix (185, 189).
Wnt
Wnts constitute a family of 19 secreted glycoproteins, whose dys-
regulation plays an important role in the progression of many
cancers including breast, gastric, prostate, melanoma, and glioblas-
toma (190, 191). Wnt ligands bind to a seven-pass transmembrane
receptor composed of Lrp5/6 and frizzled genes to transduce sig-
nals to the cytoplasmic protein Disheveled (Dsh). Dsh blocks
GSK-β to inhibit β-catenin phosphorylation, by disrupting the
β-catenin/Axin complex, leading to β-catenin stabilization, and
its nuclear translocation to interact with TCF/LEF transcrip-
tion factors (192, 193). Loss of APC activates the Wnt pathway
by stabilizing β-catenin. Loss-of-function of APC mutations is
common in many cancers (193–195). Increased nuclear β-catenin
expression correlated with advanced, metastatic, and hormone-
refractory prostate carcinoma (196). Upregulation of the Wnt
pathway by means of increased Wnt secretion, decreased expres-
sion of inhibitors such as APC, sFRP, DKK1, or Wif1, or constitu-
tive activation of β-catenin, induces the activation of downstream
target genes like c-Myc, c-Jun, and various other genes important
in both cancer development and metastasis (91, 192, 193). MMP-
14, which promotes invasion and metastasis of cancer cells, is also
a direct target of β-catenin/TCF signaling (197). The exact mech-
anisms that lead to elevated β-catenin in PCa are not clear, but it
is not usually due to APC mutation (194).
Within the bone, Wnt signaling promotes osteoblast differenti-
ation by directly stimulating Runx2 expression in osteoblasts both
in vivo and in vitro (198). Wnt signaling also stimulates BMP-2
expression, inducing the trans-differentiation of non-osteogenic
cells into osteoblasts (199). Wnt signaling may contribute to the
osteoblastic phenotype. Blocking DDK1 expression in PC3 cells,
which releases the block on Wnt signaling, switched the normal
osteolytic phenotype induced by PC3 cell to osteoblastic. Con-
versely, overexpressing DKK-1 in C4-2B cells converted the normal
mixed lesion to an osteolytic lesion (200). Thus, Wnt signaling
contributes to PCa osteoblastic bone lesions. Further investiga-
tions in the specific components of the Wnt pathway involved,
and determining if they also contribute to metastasis per se will be
important.
Platelet-derived growth factor
Platelet-derived growth factor, a potent growth factor which plays
an important role in tumor progression, consists of disulfide-
bonded homodimer polypeptide chains of A, B, C, D, and het-
erodimer AB (201). Aberrant signaling through PDGF receptors
promotes progression of many tumors, including PCa. PDGFRβ,
which is frequently activated in bone-metastatic PCa patients, is
activated both by PDGF-B and PDGF-D (202). PDGF-D, which
promotes PCa cell proliferation and tumor growth, is overex-
pressed in prostate tumors with increasing Gleason score (203).
Furthermore, PDGF also stimulates the interaction of PCa cells
with bone stromal cells. In the bone microenvironment, PDGF
is synthesized by platelets, macrophages, osteoclasts, endothe-
lial cells, and all cells differentiating from mesenchymal stem
cells, including pericytes, and osteoblasts (204). Thus, PDGF has
the potential to act as a central connector for many interac-
tions within the bone microenvironment that influence tumor
growth. Blocking PDGF receptor signaling inhibits the growth
of human breast and pancreatic cancer in bones (205, 206),
and subsequently reduces bone resorption. However, a phase
I clinical trial with a potent PDGFR inhibitor, imatinib mesy-
late in combination with docetaxel, in castration-resistant PCa
patients with bone metastasis did not show any improvement in
the median progression-free survival of patients, as compared
to docetaxel alone (207). However, imatinib mesylate inhibits
many other kinases, like Abl and c-Kit (208). Whether PDGFR
inhibitors in combination with the second generation anti-
androgens, Enzalutamide or abiraterone, will be more effective
should be investigated.
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FACTORS RELEASED FROM THE BONE MICROENVIRONMENT
Transforming growth factor-β
Transforming growth factor-β is one of the most abundant
cytokines which induces osteoblast proliferation but inhibits its
differentiation (209, 210). The effects of TGF-β on osteoclasts
are controversial. Most of the studies investigating TGF-β in can-
cer bone metastasis have focused on osteolytic bone metastasis
of breast and cancers other than PCa. A “vicious cycle” model
has been proposed to explain TGF-β signaling and osteolytic
bone metastasis. TGF-β, signaling through Gil2, in a Hedge Hog-
independent manner, stimulates the expression of parathyroid
hormone-related protein (PTHrP), which activates osteoclasts
(211). In turn, more TGF-β is released after bone resorption, which
further enhances cancer growth and osteoclast activation, initiat-
ing a “vicious cycle” (212, 213). Inhibition of TGF-β decreases
osteolytic lesions induced by breast and melanoma cancer cells in
mouse tibia (214–216). In the first report on the role of TGF-β in
PCa bone metastasis, it was found that loss of TGF-β responsive-
ness in the fibroblasts induced the up regulation of CXCL16 and
CXCL1, which promoted PCa cells adhesion to the bone matrix,
and promoted mixed (osteoblastic/osteolytic) metastatic lesions
(217). Thus, it will be important to further investigate the cell-
specific role of TGF-β in the bone microenvironment on PCa
osteoblastic bone metastasis.
Insulin-like growth factor
High serum levels of insulin-like growth factor are associated with
higher risk of breast, prostate, and colorectal cancer. Signaling
through IGF1R promotes cell proliferation, apoptosis, and inva-
sion of cancer cells; which are all integral steps in cancer metastasis
(218). For example, inhibition of IGF-1R diminishes the invasion
of PCa cells and also inhibits expression of MMP-2, an extracellu-
lar protease necessary for invasion (219). The ability of IGF-1 to
induce PCa cell proliferation and survival is dependent on loss of
Pten, a tumor suppressor commonly lost in PCa (220). However,
IGF is another important coupling factor in the bone, activat-
ing both bone formation and resorption. IGF, which promotes
proliferation, invasion, and metastasis of cancer cells is released
during bone resorption (84). One interesting study showed that
neutralizing antibody to IGF, but not antibody to TGF-β, FGF, or
PDGF, blocked the breast cancer anchorage-independent growth
induced by resorbed bone extract; further supporting a unique role
for IGF-1 in bridging the cross talk between the bone microenvi-
ronment and the cancer cells (221). Bone-derived IGF promoted
bone metastasis of breast cancer cells by stimulating prolifera-
tion and inhibiting apoptosis of cancer cells (221). Elevated IGF-1
receptor expression in the stroma surrounding clinical PCa sam-
ples correlates with high Gleason score (222). Thus, IGF-1 released
from the bone could stimulate the stroma to support PCa growth.
Indeed, blocking IGF-1 and IGF-1 receptor inhibits PCa growth
in the bone and reduced the osteoblastic bone formation. Thus,
IGF-1 signal inhibition could be strategy for limiting PCa bone
metastasis.
Fibroblast growth factor
Fibroblast growth factor, a family of ubiquitously expressed and
secreted factors, regulates processes like development, wound
healing, and neoplastic transformation through mitogenesis and
angiogenesis. Increased expression of some growth factors from
the FGF family and their receptors are reportedly associated with
PCa progression. Aberrant activation of FGF receptors (FGFR)
induces the activation of downstream targets like PI3K, MAPK,
and STAT3, all of which play an important role in the progression
of PCa (223–225). One of the FGF family members, FGF-1 (acidic
FGF) is expressed in a majority of PCa and its expression is asso-
ciated with high Gleason score (226). Levels of FGF-2 (basic FGF)
and FGF-6 are also elevated in PCa tissues as compared to normal
(227, 228). In one transgenic mouse model, FGFR1 overexpres-
sion led to PIN (229), but in another model, activated FGFR1
promoted adenocarcinoma and metastasis to lymph nodes and
liver (230). FGF may promote PCa metastasis via regulation of cell
survival (231). PCa bone metastases express FGF-8 and/or FGF-9,
and both of these FGFs are reported to promote osteoblast differ-
entiation and new bone formation (232–234). FGF-9 expression
is also associated with high Gleason score and neutralizing anti-
body against FGF-9 inhibited bone formation and bone lesions in
mice (232, 235). On the other hand, other family members, like
FGF-7 and FGF-10, are required for normal differentiation of nor-
mal prostate epithelial cells (236). Nonetheless, overexpression of
FGF-7 in a transgenic mouse prostate epithelium led to PIN (237),
and overexpression of FGF-10 in the mesenchyme in the prostate
regeneration mouse model was sufficient to induce multifocal PIN
had low-grade PCa (238). Thus, the context and level of FGF
signaling may differentially impact PCa development and progres-
sion. The mechanisms that underlie the differential expression of
FGF members and their respective receptors to promote or inhibit
PCa growth in different microenvironments, and the cellular
constituents upon which it acts need to be better resolved in PCa.
CHALLENGES THAT REMAIN
The high dependence of host environmental factors on metasta-
tic processes necessitates the use of animal models to clarify
and demonstrate that dependency. The most commonly used
model is the mouse, which has a physiology and prostate organ
structure that is significantly different from human. Nonethe-
less, valuable insight can be gleaned from the proper models.
Unfortunately, for PCa researchers many of the current mouse
models fail to fully recapitulate human disease progression; i.e., an
AR-dependent tumor growing in the prostate gland that spon-
taneously metastasizes to the bone to from an AR-dependent
osteoblastic cancer.
Models using genetic introduction of known PCa-associated
mutations into the mouse genome, rarely metastasize to the bone.
The few models that do are neuroendocrine or use mutations not
reported to be present in human disease. Nonetheless, one uni-
fying theme in the models that do produce significant metastases
is the abrogation of p53. While p53 loss is reported in <20% of
metastatic PCa tumors, other mutations that indirectly alter p53
function remain a strong possibility. Another tumor suppressor,
Pten, whose homozygous loss strongly correlates with metastatic
progression in human cancer, but whose loss alone in the mouse
does not lead to metastatic bone disease, may also contribute to
metastasis. Interestingly, both p53 and Pten impact chromosomal
stability (239), disruption of which is thought to be necessary
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for the selection of genetic variants within the tumor that even-
tually evolve the capacity to metastasize. Recent studies suggest
that EMT-associated transcription factors suppress p53 signal-
ing and impact DNA repair; thus, linking disease progression by
the tumor microenvironment with chromosomal instability (106).
Identifying the factors that specifically lead to chromosomal insta-
bility, the genetic alterations within PCa that promote metastasis,
and how the tumor microenvironment influences this, has the
potential to significantly increase our understanding of metastatic
conversion in PCa.
Several metastatic PCa cell lines isolated from bone metastases,
either from human samples or mouse xenografts (VCaP, C4–2,
PC3), retain high capacity to grow when implanted directly into
the bone, or in a few cases when injected into the heart. Two
PCa lines, one isolated from the brain, DU145, and one from
ascites, ARCaP, can also grow when implanted in bone; how-
ever, the LNCaP line isolated from a lymph node grows poorly
in the bone. Most of them, when implanted orthotopically in the
prostate, do not metastasize to the bone; though some make it
to the lung. ARCaP was reported to metastasize to the bone after
orthotopic injection (240). This was accompanied by EMT con-
version. Only a few of these, when implanted in the bone, make
osteoblastic lesions (DU145, C4–2, ARCaP). Thus, whatever prop-
erties these cells once had in the human host that permitted their
full metastatic progression in humans has been lost. Furthermore,
at least 3 of these lines, PC3, DU145, and ARCaP express AR at
such low levels they do not use the AR-regulated pathways seen in
over 90% of human PCa metastases. The LuCaP series of human
xenografted and SubQ-passaged tumors (241), isolated primarily
from soft tissue metastases and still expressing AR, can grow and
form osteoblastic lesions when implanted in the bone. Removal
of primary LuCaP tumors following orthotopic injection, allowed
the development of micrometastases to lymph nodes and soft tis-
sues (242), but not bone. Thus, these studies indicate that many
PCa tumor cell lines, whether they originally came from bone or
not, have a high capacity to grow in bone. However, they all lack
the ability to home to bone from the prostate, and their capac-
ity to induce osteoblastic lesions is variable. Developing human
lines or mouse models that can display the full metastatic progres-
sion, either through selection or genetic manipulation, remains the
Holy Grail for understanding PCa metastasis and having models
that can be used for effective therapy development and testing.
CONCLUSION AND PERSPECTIVES
Metastasis is the major cause of PCa death. Understanding how
cancer cells metastasize toward the bone is needed to design drugs
that prevent or interfere with PCa metastasis. Many studies sug-
gest that EMT transcription factors drive the initial phases of
PCa metastasis, although the events, either within the tumor or
contributed by the tumor microenvironment, that trigger EMT
specifically in PCa are still not known. Overexpression of EMT
transcription factors, in conjunction with responses to host-
derived chemotactic factors, might lead to PCa-specific homing
and metastasis to the bone. Once PCa is disseminated in the
bone, the cross talk between the bone microenvironmental fac-
tors and the PCa tumor cells contribute to the establishment of
osteoblastic lesions. The factors mediating this cross talk and their
signaling pathways need to be further delineated to ultimately halt
the progression of metastatic lesions in the bone. The develop-
ment of better animal models that fully recapitulate the metastatic
process as seen in human disease is paramount to deciphering the
molecular events associated with PCa metastasis.
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